Original articles

Bogsrud TV, Londalen A, Brandal P, Leske H, Panagopoulos I, Borghammer P, Bach-Gansmo T (2019)
18F-Fluciclovine PET/CT in Suspected Residual or Recurrent High-Grade Glioma
Clin Nucl Med, 44 (8), 605-611
DOI 10.1097/RLU.0000000000002641, PubMed 31274605

Stokke C, Blakkisrud J, Løndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A (2018)
Pre-dosing with lilotomab prior to therapy with ¹⁷⁷Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
Eur J Nucl Med Mol Imaging, 45 (7), 1233-1241
DOI 10.1007/s00259-018-3964-9, PubMed 29470615

Blakkisrud J, Holtedahl JE, Løndalen A, Dahle J, Bach-Gansmo T, Holte H, Nygaard S, Kolstad A, Stokke C (2017)
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate ¹⁷⁷Lu-Lilotomab Satetraxetan
J Nucl Med, 59 (4), 704-710
DOI 10.2967/jnumed.117.195347, PubMed 28848035

Blakkisrud J, Løndalen A, Dahle J, Turner S, Holte H, Kolstad A, Stokke C (2016)
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate
J Nucl Med, 58 (1), 55-61
DOI 10.2967/jnumed.116.180471, PubMed 27587710

Blakkisrud J, Løndalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T, Holte H, Kolstad A, Stokke C (2016)
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
J Nucl Med, 58 (1), 48-54
DOI 10.2967/jnumed.116.173922, PubMed 27493270

Bach-Gansmo T, Wien TN, Løndalen A, Halvorsen E (2014)
Myocardial uptake of bone scintigraphic agents associated with increased pulmonary uptake
Clin Physiol Funct Imaging, 36 (3), 237-41
DOI 10.1111/cpf.12219, PubMed 25524030

Other articles

Berg AS, Løndalen A, Brustugun OT (2015)
[Typical growth pattern in malignant pleural mesothelioma]
Tidsskr Nor Laegeforen, 135 (11), 1050
DOI 10.4045/tidsskr.14.0480, PubMed 26080781